Literature DB >> 21063849

Elevated homocysteine and C-reactive protein levels independently predict worsening prognosis after stroke in Chinese patients.

Jiangtao Yan1, James K Liao, Daowen Wang.   

Abstract

Increased plasma total homocysteine (tHcy) and high sensitivity C-reactive protein (hsCRP) levels are independent risk factors for cardiovascular disease. However, the predictive value of tHcy in combination with hsCRP in patients with stroke is not known. To determine the relationship between tHcy and hsCRP, we enrolled 291 patients with first-onset stroke (196 ischemic and 95 hemorrhagic). Plasma tHcy and hsCRP levels were measured and subsequent vascular events and deaths were determined over a 5-year period. Using the arbitrary cutoff for tHcy (<18 μmol/L and ≥18 μmol/L) and hsCRP (<1 mg/L, 1-3 mg/L and >3 mg/L), the patients were divided into 6 groups. Survival analysis showed that the probability of death or new vascular events during a 5-year follow-up increased according to tHcy and hsCRP levels (P<0.01). The relative risk (RR) of death or new vascular events was 4.67 (95% CI, 1.96 to 11.14, P=0.001) in patients with high tHcy (≥18 μmol/L) and hsCRP (>3 mg/L) compared with those with low tHcy (<18 μmol/L) and hsCRP (<1 mg/L). The increased tHcy level (≥18 μmol/L) combined with increased hsCRP level (>3 mg/L) was still significantly associated with the risk of death or new vascular events (RR, 4.10, 95% CI, 1.61 to 10.45, P=0.003) even when adjusted for other risk factors at inclusion. The combination of increased tHcy and hsCRP levels had a stronger predictive value than increased hsCRP alone or increased tHcy level alone. Further studies are required to evaluate the potential decrease in risks associated with lowering both Hcy and hsCRP levels in patients that present with both increased tHcy and hsCRP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063849      PMCID: PMC3807101          DOI: 10.1007/s11596-010-0557-7

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  31 in total

1.  MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

Authors:  Mariska Klerk; Petra Verhoef; Robert Clarke; Henk J Blom; Frans J Kok; Evert G Schouten
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

Review 2.  Impaired homocysteine metabolism and atherothrombotic disease.

Authors:  P Durand; M Prost; N Loreau; S Lussier-Cacan; D Blache
Journal:  Lab Invest       Date:  2001-05       Impact factor: 5.662

3.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

4.  Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study.

Authors:  N S Rost; P A Wolf; C S Kase; M Kelly-Hayes; H Silbershatz; J M Massaro; R B D'Agostino; C Franzblau; P W Wilson
Journal:  Stroke       Date:  2001-11       Impact factor: 7.914

5.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Authors: 
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

6.  Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk.

Authors:  Geoffrey H Tofler; Ralph B D'Agostino; Paul F Jacques; Andrew G Bostom; Peter W F Wilson; Izabela Lipinska; Murray A Mittleman; Jacob Selhub
Journal:  Thromb Haemost       Date:  2002-11       Impact factor: 5.249

7.  Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease.

Authors:  Maged Y Z Youssef; Olusegun A Mojiminiyi; Nabila A Abdella
Journal:  Transl Res       Date:  2007-05-25       Impact factor: 7.012

8.  Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response.

Authors:  C Zhang; Y Cai; M T Adachi; S Oshiro; T Aso; R J Kaufman; S Kitajima
Journal:  J Biol Chem       Date:  2001-07-10       Impact factor: 5.157

9.  Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.

Authors:  David S Wald; Malcolm Law; Joan K Morris
Journal:  BMJ       Date:  2002-11-23

Review 10.  Inflammatory bio-markers and cardiovascular risk prediction.

Authors:  G J Blake; P M Ridker
Journal:  J Intern Med       Date:  2002-10       Impact factor: 8.989

View more
  5 in total

1.  Prognostic value of inflammatory mediators in 1-year outcome of acute ischemic stroke with middle cerebral artery stenosis.

Authors:  Xiping Gong; Xinying Zou; Liping Liu; Yuehua Pu; Yilong Wang; Yuesong Pan; Yannie O Y Soo; Thomas W H Leung; Xingquan Zhao; Yongjun Wang; Ka Sing Wong
Journal:  Mediators Inflamm       Date:  2013-08-19       Impact factor: 4.711

2.  Effect of Nonsurgical Periodontal Therapy on Serum Highly Sensitive Capsule Reactive Protein and Homocysteine Levels in Chronic Periodontitis: A Pilot Study.

Authors:  Siddharth Mallapragada; Jyoti Kasana; Pallavi Agrawal
Journal:  Contemp Clin Dent       Date:  2017 Apr-Jun

3.  Association of Hyperhomocysteinemia with Increased Coronary Microcirculatory Resistance and Poor Short-Term Prognosis of Patients with Acute Myocardial Infarction after Elective Percutaneous Coronary Intervention.

Authors:  Yang-Pei Peng; Ming-Yuan Huang; Yang-Jing Xue; Jia-Lin Pan; Cong Lin
Journal:  Biomed Res Int       Date:  2020-01-02       Impact factor: 3.411

4.  Association of Inflammatory Markers/Cytokines with Cardiovascular Risk Manifestation in Patients with Endometriosis.

Authors:  Uzma Rafi; Shaaf Ahmad; Syeda Shazia Bokhari; Muhammad Amir Iqbal; Amna Zia; Muhammad Amjad Khan; Nabila Roohi
Journal:  Mediators Inflamm       Date:  2021-10-31       Impact factor: 4.711

Review 5.  Monomeric C-Reactive Protein and Cerebral Hemorrhage: From Bench to Bedside.

Authors:  Mario Di Napoli; Mark Slevin; Aurel Popa-Wagner; Puneetpal Singh; Simona Lattanzi; Afshin A Divani
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.